Tesla arrives at Q2 earnings week — the print is scheduled for July 22 — with a fresh wave of upward analyst revisions, a short book that has barely moved, and options traders who remain conspicuously calm.
The pre-earnings analyst traffic has been unusually active. Morgan Stanley raised its target to $417 on July 14, maintaining Equal-Weight. Barclays moved to $370 the same morning, also keeping Equal-Weight. Both adjustments came on the morning of the 14th, suggesting coordinated pre-earnings housekeeping rather than a change of view. The more meaningful signal came from UBS on July 9, lifting its target from $364 to $442 — the largest single move in the recent cluster — while staying at Neutral. RBC's Tom Narayan, previously noted in this space, raised to $500 on July 7 and remains the most bullish of the bellwether names. The outlier is Wells Fargo, which nudged its Underweight target up from $125 to $130 on the 14th — directionally higher but structurally bearish, implying a roughly 67% downside from current levels. The consensus mean landed at $425.61, a few dollars above Tesla's close of $396.18. The picture that emerges is a Street in holding pattern: nearly everyone is raising targets modestly, almost nobody is changing their rating.
Short positioning offers no drama heading into the print. SI ticked up to 2.38% of the free float — slightly lower than the 2.9–3.0% range that prevailed through June, a level change consistent with prior reporting in this series. The direction of travel is mildly higher: SI is up about 1.2% on the week and 2.9% over the past month, but those are small moves on an already-small base. Cost to borrow has eased sharply, dropping to 0.27% from 0.57% a week ago and well off the 0.97% spike seen in early June. Borrow availability is effectively unlimited — shares available dwarf the short book by orders of magnitude, meaning there is no mechanical squeeze pressure in this name. The ORTEX short score is a steady 31.7, barely budging all week, consistent with a stock that bears are watching rather than pressing.
Options traders are equally unhurried. The put/call ratio is 0.741 — fractionally below its 20-day average of 0.742, which is itself barely a rounding error from neutral. The PCR z-score of -0.11 is as close to flat as the data gets. By comparison, the 52-week high on the PCR was 1.02; the current reading is nowhere near that defensive extreme. The picture is one of orderly positioning: neither aggressive hedging nor unusual call buying ahead of a print that April's history suggests can move the stock by roughly 3% in either direction.
The most notable item in the ownership data is not institutional — it is Elon Musk's own book. The CEO sold 17.5 million shares on June 16 at around $404.66, a transaction worth approximately $7.1 billion. That is the dominant line item in the 90-day insider ledger, which shows net sales of nearly 17.6 million shares and net proceeds above $7.1 billion. CFO Vaibhav Taneja's activity is immaterial by comparison — a routine award followed by small sales in June. The June Musk sale is the largest single insider event in the available record and occurred with the stock near current prices. It does not change the setup heading into July 22, but it is the context behind any insider-flow reading.
What matters most from here is whether the Q2 delivery data — already published, showing meaningful improvement — translates into a forward margin guide that justifies the current 176x PE and 85x EV/EBITDA. The Street has spent two weeks raising targets without changing ratings. The earnings call is where that contradiction either resolves or deepens.
See the live data behind this article on ORTEX.
Open TSLA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
